Investing.com - Humacyte reported on Thursday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Humacyte announced earnings per share of $-0.25 on revenue of $30K. Analysts polled by Investing.com anticipated EPS of $-0.23 on revenue of $236.02K.
Humacyte shares are down 23.1% from the beginning of the year, still down 74.30% from its 52 week high of $12.22 set on November 17, 2021.
Humacyte follows other major Healthcare sector earnings this month
Humacyte's report follows an earnings beat by UnitedHealth on October 14, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on October 18 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar